Frost & Sullivan: A 10 Percent Yearly Rise in the Price of Branded Drugs Keeps the Indonesian NSCLC Drugs Market Afloat

Informations

• Publié par: frost-sullivan
• Nombre de lectures: 6
• Langue: English

Extrait

Frost & Sullivan: A 10 Percent Yearly Rise in

the Price of Branded Drugs Keeps the

Indonesian NSCLC Drugs Market Afloat

PR Newswire

JAKARTA, Indonesia, June 6, 2012

-

Higher Numbers of Smokers Keep the Patient Pool from Shrinking

JAKARTA, Indonesia

,

June 6, 2012

/PRNewswire/ -- Branded NSCLC drugs in

Indonesia

cost almost three times as much as generic drugs. Their high prices

are expected to compensate manufacturers for the decline in sales volumes, as

generics is the first line and often, the only form of drug treatment for NSCLC in

Indonesia

.

New analysis from Frost & Sullivan (http://www.pharma.frost.com),

The Non-

small Cell Lung Cancer Drug Market in

Indonesia

, finds that the market

earned revenues of

$16.0 million

in 2010 and estimates this to reach

$26.0

million

in 2015.

Branded drugs are sold at price-per-cycle and their volumes drop when the

price-per-cycle crosses

$850

. As the price-per-cycle of generic drugs has not

reached the

$850

mark yet, their volume is expected to continue rising.

The prices of both generic and branded NSCLC drugs could see a spurt along

with the increase in transportation and oil costs, since active pharmaceutical

ingredients (APIs) are generally imported. However, the market will be

sustained by the increasing incidence of NSCLC caused by the high rates of

smokers.

"The percentage of adult male smokers has increased from 53 percent in 1995

to 66 percent in 2010; and while only 4.2 percent of adult Indonesian women

smoke, their numbers have also increased from the 1.7 percent in 1995," says

Frost & Sullivan Research Analyst Poornima Srinivasan. "Furthermore,

approximately 97.0 million non-smokers are routinely exposed to secondhand

smoke (SHS) and 70.0 percent of children under the age of 15 are regularly

exposed to SHS, expanding the market for NSCLC drugs."

Eugene van de Weerd, Country Director, Frost & Sullivan –

Indonesia

notes that

Indonesia

also has one of the highest number of child smokers in the world,

with 25.0 percent of children over the age of 3 having tried cigarettes. This is

likely to cause the onset of tobacco-related illnesses, which includes NSCLC, to

occur at earlier ages.

"In addition, cigarettes are relatively cheap and taxes levied by the

government, at 37.0 percent of the sales price, are low in comparison to the

global standard of 70.0 percent," Eugene says. "Without higher cigarette sales

taxes and comprehensive cigarette cessation programs, smoking rates will

remain high in

Indonesia

and increase the likelihood of cancer."

Both patent expirations and the introduction of novel NSCLC drugs will widen

the drug options for patients, even though the standard first line of therapy will

continue to be a platinum-based generic chemotherapy combination. The

NSCLC market in

Indonesia

will remain loyal to generic drugs due to the low

level of patient affordability. While rising incomes will make private insurance